The Hemophilia A (Factor VIII Deficiency) drugs in development market research report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Hemophilia A (Factor VIII Deficiency). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Hemophilia A (Factor VIII Deficiency) and features dormant and discontinued products.
GlobalData tracks 99 drugs in development for Hemophilia A (Factor VIII Deficiency) by 82 companies/universities/institutes. The top development phase for Hemophilia A (Factor VIII Deficiency) is preclinical with 39 drugs in that stage. The Hemophilia A (Factor VIII Deficiency) pipeline has 92 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Hemophilia A (Factor VIII Deficiency) pipeline products market are: Beijing Neoletix Biological Technology, Zhengzhou Gensciences and Ascension Healthcare.
The key targets in the Hemophilia A (Factor VIII Deficiency) pipeline products market include Coagulation Factor VIII, Coagulation Factor X, and Coagulation Factor VII.
The key mechanisms of action in the Hemophilia A (Factor VIII Deficiency) pipeline product include Coagulation Factor VIII Activator with 35 drugs in Pre-Registration. The Hemophilia A (Factor VIII Deficiency) pipeline products include six routes of administration with the top ROA being Intravenous and 15 key molecule types in the Hemophilia A (Factor VIII Deficiency) pipeline products market including Gene Therapy, and Recombinant Protein.
Hemophilia A (Factor VIII Deficiency) overview
Hemophilia A is an X-linked recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury, or in the case of severe hemophilia, spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, spontaneous bleeding, and prolonged bleeding from cuts, tooth extraction, and surgery.
For a complete picture of Hemophilia A (Factor VIII Deficiency)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
